2SPD-010 Indirect comparison of pembrolizumab plus chemotherapy versus pembrolizumab in lung cancer

MD Gil-Sierra; S Fenix-Caballero; M Sanchez-Hidalgo; C Alarcon de la Lastra Romero; MDP Briceño-Casado; E Rios-Sanchez; J Diaz-Navarro; C Martinez-Diaz; M Camean-Castillo; JM Borrero-Rubio; E Alegre-Del Rey

doi:10.1136/ejhpharm-2019-eahpconf.50

Article info

PDF

Section 2: Selection, Procurement and Distribution

2SPD-010 Indirect comparison of pembrolizumab plus chemotherapy versus pembrolizumab in lung cancer

Free

Authors

MD Gil-Sierra 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
S Fenix-Caballero 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
M Sanchez-Hidalgo 2Universidad de Sevilla, Pharmacology Department, Sevilla, Spain PubMed articles Google scholar articles
C Alarcon de la Lastra Romero 2Universidad de Sevilla, Pharmacology Department, Sevilla, Spain PubMed articles Google scholar articles
MDP Briceño-Casado 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
E Rios-Sanchez 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
J Diaz-Navarro 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
C Martinez-Diaz 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
M Camean-Castillo 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
JM Borrero-Rubio 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles
E Alegre-Del Rey 1Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain PubMed articles Google scholar articles

Citation

Gil-Sierra M, Fenix-Caballero S, Sanchez-Hidalgo M, et al

2SPD-010 Indirect comparison of pembrolizumab plus chemotherapy versus pembrolizumab in lung cancer

European Journal of Hospital Pharmacy 2019;26:A23-A24.

Publication history

First published March 11, 2019.

Online issue publication

May 12, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password